August 30, 2011 08:08 ET

Biochip Market to Reach $5.6 Billion by 2015

ROCKVILLE, MD--(Marketwire - Aug 30, 2011) - has announced the addition of the new market intelligence report "Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015)," to their collection of Biotechnology market research. For more information, visit

A biochip is defined as a collection of miniaturized test sites (microarrays) arranged on a solid platform that allows multiple tests to be performed at the same time with increased efficiency and higher speed. This report studies the global biochip market by the types and key applications. The market was valued at $2.6 billion in 2010 and is expected to reach $5.6 billion by 2015; growing 16.7% annually through the forecast period. This growth is attributed to increasing applications in cancer diagnostics and expression profiling, the boom in personalized medicine, and government funding.

DNA microarrays represent the largest biochip market segment and will continue to be the largest contributor during the study period (2010-2015). However, this segment will be closely followed by lab-on-chip (LOC) in the coming years due to its wide applications and increased adoption by various biotechnology, pharmaceutical companies, and research laboratories. The third largest segment -- protein microarrays will be the fastest growing segment; forecasted to grow at a CAGR of 19.9% during the study period due to advances in the fields of genomics and proteomics and improvements in the field of recombinant proteins.

Reverse phase protein microarrays designed for targeted therapies in cancer holds promise in the global biochip market in the next 5-10 years. These microarrays provide increased accuracy and enhanced efficacy for the detection of rare molecules as compared to existing microarray surfaces for cancer research & diagnosis to help understand the proteins in tumor cells. Thus, they have helped open the avenues for personalized methods for cancer therapy.

The market of Asia will account for a bulk of the future biochip market growth due to its high growth potential and huge demand from emerging economies such as India and China -- the large pool of heterogeneous patient population, and increasing R&D investment in these countries. The top players in the biochip market such as Affymetrix, Inc., Illumina, Inc., and Fluidigm Corporation have relocated their manufacturing base to Singapore to take advantage of the benefits the country offers; coupled with rising demand from neighboring countries of Asia. The players also benefit from a well-established semiconductor manufacturing base including chip technologies. Singapore has made focused efforts to attract life sciences corporates with dedicated investments accounting for 3% of the country's GDP. It came up with its R&D center -- Singapore's Biopolis R&D center in 2003-2004 and is home to the Genome Institute of Singapore.

For more information, visit

About is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact